Adicet Bio Ownership
| ACET Stock | USD 0.90 0.01 1.10% |
Shares in Circulation | First Issued 2007-12-31 | Previous Quarter 90.6 M | Current Value 90.8 M | Avarage Shares Outstanding 29 M | Quarterly Volatility 14.7 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Adicet |
Adicet Stock Ownership Analysis
About 76.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.38. Some equities with similar Price to Book (P/B) outperform the market in the long run. Adicet Bio has Price/Earnings To Growth (PEG) ratio of 0.82. The entity recorded a loss per share of 1.7. The firm last dividend was issued on the 16th of September 2020. Adicet Bio had 1:7 split on the 16th of September 2020. Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 86 people. For more info on Adicet Bio please contact BA CPA at 650 503 9095 or go to https://www.adicetbio.com.Adicet Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Adicet Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Adicet Bio backward and forwards among themselves. Adicet Bio's institutional investor refers to the entity that pools money to purchase Adicet Bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Rtw Investments, Llc | 2024-06-30 | 1.1 M | Blackrock Inc | 2024-06-30 | 1 M | D. E. Shaw & Co Lp | 2024-06-30 | 836 K | Cowen And Company, Llc | 2024-06-30 | 801.3 K | Octagon Capital Advisors Lp | 2024-06-30 | 767.8 K | Geode Capital Management, Llc | 2024-06-30 | 671 K | Alyeska Investment Group, L.p. | 2024-06-30 | 655.7 K | Two Sigma Investments Llc | 2024-06-30 | 631.1 K | Stonepine Capital Management Llc | 2024-06-30 | 609.4 K | Orbimed Advisors, Llc | 2024-06-30 | 11.4 M | Tang Capital Management Llc | 2024-06-30 | 8.2 M |
Adicet Bio Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Adicet Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Adicet Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Adicet Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Schor Chen over a month ago Acquisition by Schor Chen of 421600 shares of Adicet Bio at 2.14 subject to Rule 16b-3 | ||
Aya Jakobovits over three months ago Disposition of 26400 shares by Aya Jakobovits of Adicet Bio at 2.14 subject to Rule 16b-3 | ||
Aya Jakobovits over three months ago Acquisition by Aya Jakobovits of 5900 shares of Adicet Bio subject to Rule 16b-3 | ||
Sanna Bastiano over six months ago Disposition of 28828 shares by Sanna Bastiano of Adicet Bio at 12.0 subject to Rule 16b-3 | ||
Schor Chen over a year ago Acquisition by Schor Chen of 240000 shares of Adicet Bio subject to Rule 16b-3 | ||
Schor Chen over a year ago Sale by Schor Chen of 5500 shares of Adicet Bio | ||
Silverstein Jonathan over a year ago Conversion by Silverstein Jonathan of 2425482 shares of Adicet Bio | ||
Schor Chen over a year ago Bona fide gift to Schor Chen of 26712 shares of Adicet Bio subject to Section 16 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Adicet Stock Analysis
When running Adicet Bio's price analysis, check to measure Adicet Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adicet Bio is operating at the current time. Most of Adicet Bio's value examination focuses on studying past and present price action to predict the probability of Adicet Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adicet Bio's price. Additionally, you may evaluate how the addition of Adicet Bio to your portfolios can decrease your overall portfolio volatility.